Drug-induced liver hypersensitivity disease (Q43584): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
Doença de hipersensibilidade hepática induzida por droga é uma condição, relativamente, rara, mas que pode ter consequências sérias para o indivíduo, a saúde pública, as agências regulatórias e a indústria farmacêutica. Caracteriza-se pela elevação no soro de alanina aminotransferase (ALT), bilirrubina conjugada, ou bilirrubina combinada, ALT e fosfatase alcalina (FA) por > 2 vezes o limite superior do normal; e as drogas mais frequentemente relacionadas são halotano, ácido tienílico, di-hidralazina, diclofenaco e carbamazepina.
description / endescription / en
 
Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.

Revision as of 10:39, 13 August 2026

Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.
Language Label Description Also known as
default for all languages
4A85.00
    English
    Drug-induced liver hypersensitivity disease
    Drug-induced liver hypersensitivity disease is a relatively rare condition, but can have serious consequences for the individual patient, public health, regulatory agencies and the pharmaceutical industry. It is characterised by elevation in serum alanine-aminotransferase (ALT), conjugated bilirubin, or combined bilirubin, ALT and alkaline phosphatase (AP) levels > 2 times the upper limit of normal (ULN) and the most frequent related drugs are halothane, tienilic acid, dihydralazine, diclofenac, and carbamazepine.

      Statements